ArticleEClinicalMedicine2023

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial.

Kaz Groen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.